Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Theravance one program away from joining Incyte, says Piper Jaffray

After hosting meetings with management, Piper Jaffray analyst Joshua Schimmer reiterates Theravance Biopharma (TBPH) as a top mid-cap pick. The analyst has an Overweight rating on the shares with a $42 price target. Schimmer increasingly sees Theravance as one of the most likely mid-caps to make the jump to be the next Incyte (INCY). The company is just one major program away from joining the ranks of Incyte and BioMarin (BMRN), he tells investors in a research note.

Read more at:
http://thefly.com/landingPageNews.php?id=2523382